Year 2015 / Volume 107 / Number 2
Original
Octreotide long-active release in the treatment of gastrointestinal bleeding due to vascular malformations: Cost-effectiveness study

79-88

Katerina Klímová, Camilo Padilla Suárez, álvaro Giménez Manzorro, José Antonio Pajares Díaz, Gerardo Clemente Ricote y Ana Hernando Alonso

Abstract
Introduction: Gastrointestinal hemorrhage due to vascular malformations has a negative impact on patients’ quality of life and consumes an important quantity of resources.
Objective: Analyze the cost-effectiveness of long-active releasing octreotide (OCT-LAR) in the treatment of gastrointestinal haemorrhage secondary to vascular malformations.
Material and methods: Retrospective study, including 19 pacients that were treated with mensual injections of OCT- LAR between 2008-2013. The number of blood transfusions, hemoglobin levels, hospital admissions and possible side effects during the year before treatment and the year after the start of the treatment were assessed, and cost-effectiveness was analyzed.
Results: After the beginning of the treatment with OCT- LAR, complete response was observed in 7 patients (36.8 %), partial response in 7 patients (36.8 %) and 5 patients (26.3 %) continued to require admissions, blood transfusions and/or endoscopic treatment. We observed significant reduction in the length of admission per year (in days) before and after the start of the treatment (22.79 versus 2.01 days, p < 0.0001) as well as in the number of blood transfusions administered (11.19 versus 2.55 blood transfusions per year, p = 0.002). The mean haemoglobin levels increased from 6.9 g/dl to 10.62 g/dl (p < 0.0001). We observed reduction of costs of 61.5 % between the two periods (from 36,072.35 € to 13,867.57 € per patient and year, p = 0.01). No side effects related to treatment were described.
Conclusion: In conclusion, OCT-LAR seems to be a cost- efficient and safe pharmacological treatment of gastrointestinal haemorrhage secondary to vascular malformations, mainly in patients in whom endoscopic or surgical treatment is contraindicated.
Share Button
New comment
Comments
No comments for this article
Related articles
Citation tools
Katerina Klímová, Camilo Padilla Suárez, álvaro Giménez Manzorro, José Antonio Pajares Díaz, Gerardo Clemente Ricote y Ana Hernando Alonso. Octreotide long-active release in the treatment of gastrointestinal bleeding due to vascular malformations: Cost-effectiveness study. 79-88


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 33 visits.
This article has been downloaded 33 times.
Share
This article has been rated by 1 readers.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology